TriLink BioTechnologies® and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology
TriLink BioTechnologies, a Maravai LifeSciences (NASDAQ: MRVI) company, has entered into a non-exclusive License and Supply Agreement with Aldevron for CleanCap® mRNA capping technology. The agreement allows Aldevron to use TriLink's patented CleanCap® analogs in mRNA development and manufacturing services through Phase III programs.
The agreement covers CleanCap® M6, CleanCap® AG 3'OMe, CleanCap® AG, and CleanCap® AU cap analogs. The CleanCap® technology delivers optimal 5'Cap structures with over 95% efficiency, improving mRNA yield and process time compared to traditional methods. The technology has been used in over 350 preclinical and clinical programs and is featured in most approved COVID-19 mRNA and saRNA vaccines.
Notably, the recently introduced CleanCap® M6 (May 2023) has demonstrated increased mRNA expression by more than 30% compared to enzymatic capping methods.
TriLink BioTechnologies, una società di Maravai LifeSciences (NASDAQ: MRVI), ha stipulato un contratto di Licenza e Fornitura non esclusivo con Aldevron per la tecnologia di cap mRNA CleanCap®. L'accordo consente ad Aldevron di utilizzare gli analoghi brevettati CleanCap® di TriLink nello sviluppo e nei servizi di produzione di mRNA attraverso i programmi di Fase III.
L'accordo copre gli analoghi di cap CleanCap® M6, CleanCap® AG 3'OMe, CleanCap® AG e CleanCap® AU. La tecnologia CleanCap® offre strutture 5'Cap ottimali con oltre il 95% di efficienza, migliorando il rendimento dell'mRNA e il tempo di processo rispetto ai metodi tradizionali. Questa tecnologia è stata utilizzata in oltre 350 programmi preclinici e clinici ed è presente nella maggior parte dei vaccini mRNA e saRNA approvati contro il COVID-19.
In particolare, il recentemente introdotto CleanCap® M6 (maggio 2023) ha dimostrato un aumento dell'espressione dell'mRNA superiore al 30% rispetto ai metodi di capenzimatici.
TriLink BioTechnologies, una empresa de Maravai LifeSciences (NASDAQ: MRVI), ha firmado un Acuerdo de Licencia y Suministro no exclusivo con Aldevron para la tecnología de capping CleanCap® mRNA. El acuerdo permite a Aldevron utilizar los análogos patentados CleanCap® de TriLink en el desarrollo y manufacturing de mRNA a través de programas de Fase III.
El acuerdo cubre los análogos de cap CleanCap® M6, CleanCap® AG 3'OMe, CleanCap® AG y CleanCap® AU. La tecnología CleanCap® proporciona estructuras 5'Cap óptimas con más del 95% de eficiencia, mejorando el rendimiento del mRNA y el tiempo de proceso en comparación con los métodos tradicionales. Esta tecnología ha sido utilizada en más de 350 programas preclínicos y clínicos y está presente en la mayoría de las vacunas mRNA y saRNA aprobadas contra el COVID-19.
Notablemente, el CleanCap® M6 introducido recientemente (mayo de 2023) ha demostrado un aumento de la expresión de mRNA de más del 30% en comparación con los métodos de capping enzimáticos.
TriLink BioTechnologies는 Maravai LifeSciences(NASDAQ: MRVI) 소속 회사로, Aldevron과 CleanCap® mRNA 캡핑 기술에 대한 비독점 라이선스 및 공급 계약을 체결했습니다. 이 계약은 Aldevron이 TriLink의 특허받은 CleanCap® 유사체를 mRNA 개발 및 제조 서비스에 사용할 수 있도록 허용합니다. 이 계약은 3상 프로그램을 포함합니다.
계약은 CleanCap® M6, CleanCap® AG 3'OMe, CleanCap® AG 및 CleanCap® AU 캡 유사체를 포함합니다. CleanCap® 기술은 전통적인 방법에 비해 95% 이상의 효율로 최적의 5'Cap 구조를 제공하여 mRNA 수율 및 처리 시간을 개선합니다. 이 기술은 350개 이상의 전임상 및 임상 프로그램에서 사용되었으며, 대부분의 승인된 COVID-19 mRNA 및 saRNA 백신에 포함되어 있습니다.
특히, 최근에 소개된 CleanCap® M6(2023년 5월)는 효소 기반 캡핑 방법에 비해 mRNA 발현을 30% 이상 증가시키는 것으로 나타났습니다.
TriLink BioTechnologies, une société de Maravai LifeSciences (NASDAQ: MRVI), a conclu un Accord de Licence et de Fourniture non exclusif avec Aldevron pour la technologie de cap mRNA CleanCap®. Cet accord permet à Aldevron d'utiliser les analogues brevetés CleanCap® de TriLink dans le développement et les services de fabrication de mRNA à travers des programmes de Phase III.
L'accord couvre les analogues de cap CleanCap® M6, CleanCap® AG 3'OMe, CleanCap® AG et CleanCap® AU. La technologie CleanCap® fournit des structures 5'Cap optimales avec plus de 95% d'efficacité, améliorant le rendement en mRNA et le temps de traitement par rapport aux méthodes traditionnelles. Cette technologie a été utilisée dans plus de 350 programmes précliniques et cliniques et est présente dans la plupart des vaccins mRNA et saRNA approuvés contre le COVID-19.
Notamment, le CleanCap® M6 récemment introduit (mai 2023) a démontré une augmentation de l'expression de l'mRNA de plus de 30% par rapport aux méthodes de capping enzymatiques.
TriLink BioTechnologies, ein Unternehmen von Maravai LifeSciences (NASDAQ: MRVI), hat eine nicht-exklusive Lizenz- und Liefervereinbarung mit Aldevron für die CleanCap® mRNA-Capping-Technologie abgeschlossen. Die Vereinbarung erlaubt es Aldevron, die patentierten CleanCap®-Analoge von TriLink in der Entwicklung und Herstellung von mRNA durch Phase-III-Programme zu verwenden.
Die Vereinbarung umfasst die CleanCap®-Analoge M6, AG 3'OMe, AG und AU. Die CleanCap®-Technologie liefert optimale 5'Cap-Strukturen mit über 95% Effizienz und verbessert den mRNA-Ertrag sowie die Prozesszeit im Vergleich zu traditionellen Methoden. Diese Technologie wurde in über 350 präklinischen und klinischen Programmen eingesetzt und ist in den meisten genehmigten COVID-19 mRNA- und saRNA-Impfstoffen enthalten.
Besonders zu erwähnen ist, dass der kürzlich eingeführte CleanCap® M6 (Mai 2023) eine gesteigerte mRNA-Expression um über 30% im Vergleich zu enzymatischen Capping-Methoden gezeigt hat.
- Technology used in 350+ preclinical and clinical programs
- 95% efficiency in producing optimal 5'Cap structures
- New CleanCap® M6 shows 30% higher mRNA expression vs. enzymatic methods
- Expanded market reach through non-exclusive licensing agreement
- None.
Insights
This strategic licensing agreement marks a significant expansion of Maravai LifeSciences' market reach in the rapidly growing mRNA therapeutics space. The partnership with Aldevron, a major CDMO player, positions TriLink's CleanCap® technology as an industry standard, potentially driving recurring revenue streams through both licensing fees and supply agreements.
The deal's significance is amplified by three key factors:
- CleanCap's established track record in 350+ preclinical and clinical programs, including COVID-19 vaccines, demonstrates its market dominance
- The superior efficiency of over 95% in producing optimal 5'Cap structures represents a significant competitive advantage
- The latest CleanCap® M6 variant's 30% increased expression further solidifies the technology's market leadership
From a market perspective, this agreement strategically positions Maravai to capture a larger share of the expanding mRNA therapeutics market, projected to grow significantly with applications beyond vaccines into cancer treatments and rare diseases. The non-exclusive nature of the license suggests a balanced approach between maximizing market penetration while maintaining pricing power and future partnership opportunities.
For investors, this development represents a positive catalyst for long-term growth, as it enhances Maravai's recurring revenue potential and strengthens its intellectual property monetization strategy. The partnership with Aldevron expands the technology's reach into new therapeutic programs, potentially creating multiple revenue streams from successful drug developments.
Enabling the future development of critical therapeutics, Aldevron customers now have access to TriLink’s CleanCap mRNA capping technology for non-commercial use
According to the terms of the agreement, TriLink will supply its patented CleanCap® M6, CleanCap® AG 3’OMe, CleanCap® AG, and CleanCap® AU cap analogs for use in Aldevron’s mRNA development and manufacturing services, from pre-clinical through Phase III programs. CleanCap® technology produces optimal 5’Cap structures with over
“CleanCap technology is accelerating programs through drug development milestones and has been the capping technology of choice for mRNA constructs in 350+ preclinical and clinical programs,” shared Becky Buzzeo, Chief Commercial Officer, Maravai. “We’re excited to offer our innovative capping solutions to Aldevron and its manufacturing customers.”
Since its launch in 2017, TriLink’s CleanCap® capping technology has continued to advance the mRNA capping industry and is used in the majority of all approved COVID-19 mRNA and saRNA vaccines. In May 2023, TriLink introduced its most robust CleanCap® analog to date, CleanCap® M6, with studies indicating increased mRNA expression by more than
Aldevron, based in
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders to enabling future pandemic response plans.
For more information, visit trilinkbiotech.com.
About Maravai LifeSciences
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
For more information about Maravai LifeSciences, visit maravai.com.
About Aldevron
Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, RNA, proteins, enzymes, and other key components for the development of vaccines, gene and cell therapies, immunotherapies, and other treatments. Headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204333920/en/
Media contact:
Liz Robinson of CG Life
TriLink BioTechnologies
+1 312-997-2436
lrobinson@cglife.com
Ellen Shafer
Senior Director of Communications
Aldevron
O: 701-551-8704
ellen.shafer@aldevron.com
Investor contact:
Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
ir@maravai.com
Source: TriLink BioTechnologies
FAQ
What is the impact of TriLink's CleanCap licensing agreement with Aldevron on MRVI?
How efficient is MRVI's CleanCap technology for mRNA production?
What performance improvements does MRVI's new CleanCap M6 offer?
How many clinical programs use MRVI's CleanCap technology?
